Speed Bumps Ahead For IP Waiver, But Will It Nudge Voluntary Licensing?
Debate Over Need For, Impact Of Plan
IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.
